About Silexion Therapeutics Corp - Ordinary Shares (SLXN)
Silexion Therapeutics Corp is a biotechnology company focused on developing innovative therapies to address unmet medical needs in various therapeutic areas. The company specializes in the discovery and advancement of novel drug candidates utilizing its proprietary technologies. With a commitment to improving patient outcomes, Silexion aims to leverage cutting-edge research and development to create targeted treatments that enhance the quality of life for individuals suffering from complex diseases. Through collaboration with academic institutions and industry partners, Silexion strives to bring transformative healthcare solutions to market. Read More
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Silexion's SIL204 showed strong anti-tumor effects in preclinical tests, reaching major metastasis sites in pancreatic cancer models at human-relevant doses.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Silexion's SIL204 showed strong KRAS-targeted inhibition across pancreatic, colorectal, and lung cancer cells, supporting its advancement to clinical trials.
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
